Kenvue Inc. (NYSE:KVUE) Shares Purchased by Curi RMB Capital LLC

Curi RMB Capital LLC lifted its position in Kenvue Inc. (NYSE:KVUE) by 0.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 560,169 shares of the company’s stock after buying an additional 1,687 shares during the quarter. Curi RMB Capital LLC’s holdings in Kenvue were worth $11,960,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of KVUE. Vanguard Group Inc. increased its holdings in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock valued at $4,665,908,000 after buying an additional 1,636,741 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Kenvue by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock valued at $980,989,000 after purchasing an additional 1,391,854 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock valued at $912,059,000 after purchasing an additional 16,269,721 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Kenvue by 2.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company’s stock worth $533,169,000 after purchasing an additional 561,570 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of KVUE opened at $23.42 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a market cap of $44.93 billion, a PE ratio of 44.19, a PEG ratio of 2.62 and a beta of 1.02. The firm’s 50 day moving average price is $22.91 and its 200 day moving average price is $22.41. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Barclays reduced their price objective on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, April 14th. Canaccord Genuity Group lifted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Evercore ISI started coverage on Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 price target on the stock. Finally, Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average price target of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.